Detalhe da pesquisa
1.
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
Blood
; 143(9): 796-806, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871576
2.
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
HIV Clin Trials
; 16(2): 72-80, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25923596
3.
Corrigendum. Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomised, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral Agents.
HIV Clin Trials
; 16(6): 236-7, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26777796
4.
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
Antivir Ther
; 22(3): 263-269, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27924779